Persistent detection of Epstein-Barr virus DNA after pediatric liver transplantation: Unclear risks and uncertain responses

Liver Transplantation

Volumn 14, Issue 8, 2008, Pages 1077-1080

  Green, Michael ^a,b   Mazariegos, George V ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOSPORIN; GANCICLOVIR; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

DNA DETERMINATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EPSTEIN BARR VIRUS; GENE AMPLIFICATION; GRAFT INFECTION; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; MORTALITY; PATIENT MONITORING; PEDIATRIC SURGERY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; CHILD; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS;

EID: 49649115514     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21550     Document Type: Editorial

References (14)

1. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transplant Infect Dis 2001;3:70-78.
2. Green M, Reyes J, Webber S, Michaels MG, Rowe D. role of viral load in the diagnosis, management, and possible prevention of Epstein Barr virus-associated post-transplant lymphoproliferative disease following solid organ transplantation. Curr Opin Organ Transplant 1999;4: 292-296.
3. Funch DP, Walker AM, Schneider G, Ziyadeh NH, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5:2894-2900.
4. Malatach JF, Gartner JC Jr, Urbach AH, Zitelli BJ. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. J Pediatr 1991;118:667-675.
5. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and preemptive therapy of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Transplantation 1998;66: 1604-1611.
6. Green M, Caccuarelli TV, Mazareigos GV, Sigurdsson L, Qu L, Rowe DT, Reyes J. Serial measurements of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998;66:1641-1644.
7. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005;5:2222-2228.
8. Hierro L, Diez-Dorado R, Diaz C, De la Vega A, Frauca E, Camarena C, et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl 2008;14:1185-1193.
9. D'Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl 2007;13:343-348.
10. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 2008. Available at: http://www.blackwellpublishing.com. DOI: 10.1111/ j.1399-3046.2008.00926-X.
11. Green M, Webber SA. Persistent increased Epstein-Barr virus loads after solid-organ transplantation: truth and consequences. Liver Transpl 2007;13:321-322.
12. Bingler MD, Miller SA, Quivers E, Michaels MG, Green M, Wadowsky RM, et al. Chronic high Epstein-Barr viral load state and risk for late onset post-transplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008;8:442-445.
13. Cacciarrelli TV, Reyes J, Jaffee R, Mazariegos GV, Jain A, Fung JJ, Green M. Primary tacrolimus (FK506) therapy and the long-term risk of posttransplant lymphoproliferative disorder in pediatric liver transplant recipients. Pediatr Transplant 2001;5:359-364.
14. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68: 1517-1525.